InDex Pharmaceuticals published its year-end report for 2022 on February 23 2023 at 08:00 a.m. CET.

Our phase III program CONCLUDE

Have a look at InDex’s corporate presentation

CEO corner

Learn more about Jenny Sundqvist, our CEO

InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis

Proud partner of: